Oxford BioMedica has named Dr Paul Blake as chief development officer.
Dr Blake, who is already a board member at the UK-based gene therapy specialist, will assume his new role on September 1. He will head the clinical development of the company’s pipeline of gene and cell therapies.
Prior to taking the position at Oxford BioMedicia Dr Blake was senior VP and chief medical officer of Canada-based biopharma AEterna Zentaris- a position he held from 2006 to 2014.
His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.
John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”